Hyphens Pharma reported FY2025 revenue of SGD 177.4 million (-9.2%), gross profit of SGD 72.2 million (+3.8%) and a gross margin of 40.7% (up 5.1 ppt). Profit before tax was SGD 8.1 million (-37.8%) and profit after tax was SGD 6.1 million (-43.6%), with basic EPS of 1.89 Singapore cents. Net cash from operating activities was SGD 18.7 million for FY2025, and cash and cash equivalents stood at SGD 26.8 million as at 31 December 2025. By segment in FY2025, Pharmaceutical and Medical Aesthetics revenue was SGD 101.3 million (-18.4%), Proprietary Brands revenue was SGD 36.7 million (+33.1%), and Digital Platform and E-Pharmacy revenue was SGD 39.4 million (-9.8%). The company said gross margin improvement reflected portfolio optimisation and a shift toward higher-margin products, while FY2025 results were impacted by foreign exchange losses and inventory provisions and write-offs, including excess Sterimar inventory. Hyphens Pharma proposed a final dividend of 1.5 Singapore cents per share for FY2025. Operationally, Hyphens Pharma highlighted strong demand for Ceradan dermatological products and Ocean Health supplements, and noted that Winlevi was launched in Singapore and Malaysia in FY2025 with additional launches anticipated in 2026. It also said it out-licensed Cerapro MED to Louis Widmer across six European countries in early 2026, expects to complete the final tranche of its Ardence Pharma acquisition in FY2026, and is advancing its POM platform and Wellaway e-pharmacy, including deploying an AI-based e-MSL module.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hyphens Pharma International Ltd. published the original content used to generate this news brief via Singapore Exchange Limited (SGX) (Ref. ID: 7WEOZDKQ3KPZHZR8) on February 24, 2026, and is solely responsible for the information contained therein.